Scancell plc has provided a comprehensive corporate and clinical update highlighting key advancements in its immunotherapy pipeline. The company confirmed it remains on schedule to complete its NASDAQ listing, which will facilitate financing for the upcoming Phase 3 global registrational trial of its lead program, inzitagene plasmivec (iSCIB1+), targeting advanced melanoma. The Phase 3 trial is planned to commence in December 2026 following regulatory clearances earlier this year.
A major regulatory milestone was achieved with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine Advanced Therapy (RMAT) designation to iSCIB1+. This designation, alongside the previously awarded Fast Track status, recognizes the therapy’s potential to address unmet medical needs in advanced melanoma. RMAT status provides Scancell with benefits including intensive FDA guidance, eligibility for rolling and priority reviews, and accelerated approval pathways if criteria are met.
Chief Executive Officer Dr Phillip L’Huillier expressed optimism about the pipeline’s progress, stating, "The new data from the ongoing ModiFY trial demonstrate that Modi-1 can induce vaccine-specific immune responses in a subset of patients with renal cell carcinoma (RCC), with these responses being associated with longer progression-free survival. These findings provide encouraging evidence of clinical activity of our Moditope platform and support further evaluation of Modi-1."
The Phase 2 SCOPE trial evaluating iSCIB1+ in combination with checkpoint inhibitors continues to show durable clinical benefits. Data analyzed as of November 12, 2026, indicate an overall survival rate of 82% at 24 months for combined SCIB1 and iSCIB1+ cohorts (n=80), with iSCIB1+ alone demonstrating an 87% survival rate. Progression-free survival (PFS) at 24 months was 65% for the combined cohorts and 71% for iSCIB1+ specifically, outperforming the 41.5% PFS reported in the CheckMate 067 study for standard-of-care ipilimumab/nivolumab treatment.
Complete response rates have also improved, reaching 28% for the combined cohorts and 31% for the iSCIB1+ Cohort 3 subgroup. These encouraging results support the planned global Phase 3 trial, which remains on track for first patient in (FPI) in December 2026, following FDA Investigational New Drug (IND) clearance and Clinical Trial Authorization from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).
Scancell plans to request an initial comprehensive multidisciplinary RMAT meeting with the FDA to discuss the development program, including Phase 3 trial design and manufacturing strategies. Additionally, the World Health Organization (WHO) has assigned "inzitagene plasmivec" as the International Nonproprietary Name (INN) for iSCIB1+, providing a globally recognized nonproprietary identifier for regulatory and scientific use.
Beyond melanoma, Scancell’s Moditope platform is advancing in renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC) through the fully recruited Phase 2 ModiFY trial. In the RCC cohort (n=43), combining Modi-1 with ipilimumab and nivolumab yielded an objective response rate (ORR) of 48% and a median PFS of 7.8 months. Notably, 46% of RCC patients mounted vaccine-specific immune responses to Modi-1’s citrullinated peptides, correlating with superior clinical outcomes: 6-month PFS of 75% versus 50% in non-responders (p=0.0025), ORR of 58% versus 36%, and median PFS not reached at 22 months compared to 6 months in non-responders.
Safety data from the ModiFY trial indicate no toxicity beyond that expected from checkpoint inhibitors and no evidence of autoimmune disease, supporting the favorable tolerability profile of Modi-1.
Scancell is also expanding its ImmunoBody® platform by initiating research on new candidates targeting tumor-associated antigens such as KRAS, cMET, and FAP. These candidates aim to address indications including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and microsatellite stable colorectal cancer (MSS CRC).
The company anticipates releasing more mature progression-free survival and interim overall survival data from the SCOPE trial in the first half of 2027, which will further inform clinical development strategies.
Scancell’s strategic focus remains on advancing its lead immunotherapy programs while leveraging regulatory designations and clinical data to accelerate development and maximize patient benefit in oncology.
Scancell Advances Immunotherapy Pipeline with FDA RMAT Designation and Phase 3 Trial Preparations Scancell plc has announced significant corporate and clinical milestones, including FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its lead immunotherapy candidate iSCIB1+ in advanced melanoma. The co... Read the full IIPLA article: https://iipla.org/news/scancell-advances-immunotherapy-pipeline-with-fda-rmat-designation-and-phase-3-trial-preparations